Industry News

Drug targeting mutant cancer gene is highly effective, durable A drug targeting a gene fusion that occurs in lung, colon, and other cancers was effective in 75 percent of patients of all ages in clinical trials, and an even higher percentage of pediatric patients, researchers at Southwestern’s Simmons Cancer Center announced.February 21, 2018

Aimmune Therapeutics announces pricing of public offering of common stock Aimmune Therapeutics announced pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million. Aimmune granted underwriter a 30-day option to purchase an additional 825,000 shares of common stock.February 21, 2018

Advaxis announces proposed public offering of common stock Advaxis announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Advaxis intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold offered in the offering.February 21, 2018